HPV-Related Throat Cancer: Why Oropharyngeal Cancer Is Rising, How HPV Causes It, and Survival Rates

Research-informed explainer — last updated April 12, 2026

HPV-positive oropharyngeal cancer — cancer of the tonsils, base of tongue, and back of throat driven by the human papillomavirus — has a 5-year survival rate of roughly 82%, compared with approximately 35% for HPV-negative oropharyngeal cancer. This difference is so large that HPV status is now the most important prognostic factor in oropharyngeal cancer, shaping both the expected outcome and the intensity of treatment.

The epidemiology, biology, and treatment of HPV-related throat cancer have been defined by a small group of researchers over two decades. Maura Gillison, Professor of Medicine at MD Anderson Cancer Center, published the first formal evidence of a causal association between HPV and head and neck cancers (3,091 citations), the landmark 2011 paper documenting rising oropharyngeal cancer incidence in the US tied to HPV (3,574 citations), and the 2012 JAMA study measuring oral HPV prevalence nationally (1,051 citations) — establishing that 7% of Americans have oral HPV infection at any given time. Christine Chung, Senior Member and Chair of Head and Neck-Endocrine Oncology at Moffitt Cancer Center, is the last author of the 2010 NEJM study definitively establishing the survival advantage of HPV-positive oropharyngeal cancer over HPV-negative disease (6,433 citations). Alexander Colevas at Stanford contributed to CheckMate-141 establishing nivolumab as standard second-line therapy for recurrent or metastatic head and neck squamous cell carcinoma (4,970 citations) and the RTOG 1016 trial testing whether cetuximab could replace cisplatin in HPV-positive patients (1,263 citations). Tanguy Seiwert, Director of Head and Neck Cancer Oncology at Johns Hopkins and Co-Director of the Bloomberg Kimmel Institute for Immunotherapy, first authored the KEYNOTE-012 pembrolizumab trial in head and neck cancer (1,719 citations). Robert Haddad, Chief of Head and Neck Oncology at Dana-Farber, provided the comprehensive state-of-the-art treatment overview (925 citations) used in clinical training worldwide.

Why oropharyngeal cancer is rising — and who is at risk

Oropharyngeal cancer was historically linked to tobacco and heavy alcohol use. That picture has changed dramatically. Gillison's 2011 Journal of Clinical Oncology study showed that HPV-positive oropharyngeal cancers were increasing at 225% per decade in the US while HPV-negative cases (associated with tobacco/alcohol) were declining. By approximately 2010, HPV had overtaken tobacco and alcohol as the leading cause of oropharyngeal cancer in the United States.

HPV-16 is responsible for approximately 90% of HPV-associated oropharyngeal cancers. Infection occurs through oral sexual contact. National survey data (Gillison's 2012 JAMA paper) found oral HPV-16 prevalence of 1% in women and 2.6% in men, with higher rates in older men. Most oral HPV infections resolve without causing cancer — but in a subset of people, HPV DNA integrates into cells of the oropharynx and drives malignant transformation through oncoproteins E6 and E7 that inactivate tumor suppressors p53 and Rb.

The typical patient with HPV-positive oropharyngeal cancer is a middle-aged man (median age 54), a nonsmoker or light former smoker, often without obvious risk factors, who presents with a neck lump (enlarged lymph node) rather than a throat symptom. The primary tumor in the tonsil or tongue base may be small and easily missed on physical exam.

How HPV is detected in the tumor — and what it means

Tumor HPV status is determined by p16 immunohistochemistry (IHC) — a surrogate marker for HPV infection, since HPV-driven tumors overexpress p16 — or by in situ hybridization (ISH) or polymerase chain reaction (PCR) for HPV-16 DNA. p16 IHC is the most widely used test because it is inexpensive, reproducible, and strongly correlated with clinical outcomes.

A positive p16 result reclassifies oropharyngeal cancer from a disease with approximately 35% 5-year survival to one with approximately 82% 5-year survival in the landmark NEJM study by Chung and colleagues. This reclassification has led AJCC (American Joint Committee on Cancer) to create a separate staging system for p16-positive oropharyngeal cancer in the 8th edition — a patient with HPV-positive oropharyngeal cancer with three small lymph node metastases is staged as stage I under the new system.

Standard treatment: chemoradiation for most patients

Most patients with locally advanced HPV-positive oropharyngeal cancer receive concurrent platinum-based chemotherapy (cisplatin) and intensity-modulated radiation therapy (IMRT). Response rates are high, and survival outcomes are substantially better than in HPV-negative disease at the same clinical stage.

The RTOG 1016 trial (Colevas) tested whether cetuximab (a less toxic drug targeting EGFR) could replace cisplatin as the radiation-sensitizing agent in HPV-positive patients, aiming to reduce long-term toxicity. The trial showed that cisplatin plus radiation was superior to cetuximab plus radiation in HPV-positive disease — and cisplatin remains the standard chemotherapy partner for radiation in appropriate patients. Patients who cannot tolerate cisplatin due to kidney function, hearing loss, or neuropathy require individualized decisions about alternative chemotherapy partners or radiation alone.

Immunotherapy in recurrent/metastatic disease

When HPV-positive oropharyngeal cancer recurs or spreads, treatment options have improved significantly with immunotherapy. The CheckMate-141 trial (Colevas) showed that nivolumab produced a 36% improvement in overall survival versus investigator's choice chemotherapy in platinum-refractory head and neck squamous cell carcinoma. Tanguy Seiwert's KEYNOTE-012 trial established pembrolizumab's activity in recurrent/metastatic head and neck cancer including HPV-positive disease.

Pembrolizumab plus platinum-based chemotherapy is now the standard first-line regimen for recurrent/metastatic head and neck squamous cell carcinoma, based on the KEYNOTE-048 trial.

De-intensification trials: can treatment be less toxic for HPV-positive patients?

Given the excellent prognosis of HPV-positive oropharyngeal cancer, ongoing trials are testing whether treatment can be de-intensified — lower radiation doses, reduced or eliminated chemotherapy — to reduce long-term toxicity (swallowing difficulty, dry mouth, hearing loss) without compromising survival. Results from these trials, including ECOG-ACRIN E3311 and others, are expected to further reshape the treatment paradigm over the next several years. These remain experimental — standard cisplatin/radiation remains the current benchmark.

HPV vaccination: prevention, not treatment

The HPV vaccine (Gardasil 9) prevents oral HPV-16 infection when given before exposure, typically in adolescence. Vaccination rates in the United States remain below target levels, and the rise in HPV-positive oropharyngeal cancer cases reflects sexual transmission of HPV in generations before widespread vaccination. Vaccination does not treat existing HPV infection or HPV-positive cancer, but it protects younger generations from developing these cancers.

Robert Haddad's 2008 NEJM review noted that HPV was then an emerging story in head and neck cancer — as of 2026, it has become the dominant story, with the majority of new oropharyngeal cancer diagnoses being HPV-positive.

Questions to ask your doctor

• Has my tumor been tested for HPV or p16 status, and what did the result show?
• Given my HPV status and staging, what is my expected 5-year survival, and how does that compare to HPV-negative oropharyngeal cancer?
• Is there any clinical trial testing de-intensified treatment that I might be eligible for?
• What long-term swallowing and dry-mouth effects should I expect from radiation, and what can be done to minimize them?
• If I am not yet vaccinated or have unvaccinated children, is the HPV vaccine still relevant for us?

The bottom line

HPV-positive oropharyngeal cancer is a distinct disease with dramatically better outcomes than HPV-negative head and neck cancer, and the reason for that difference is the immune system's ability to recognize HPV-driven tumor cells. For newly diagnosed patients, p16 testing should be confirmed and results communicated clearly, as they fundamentally change prognosis, staging, and the framework for clinical trial eligibility. Patients should ask whether de-intensification trials are available to them, given the real long-term toxicities of current standard-of-care treatment.